Mo­men­ta’s failed pan­cre­at­ic can­cer drug is giv­en a mid­night fu­ner­al

Pan­cre­at­ic can­cer has claimed an­oth­er biotech vic­tim. The tough on­col­o­gy tar­get proved re­sis­tant to Mo­men­ta Phar­ma­ceu­ti­cals’ necu­paranib at the halfway point in their Phase II study. And now the biotech $MN­TA has de­cid­ed to deep-six the drug and move on, ac­cord­ing to an SEC fil­ing.

Mo­men­ta’s 8-K, filed on Thurs­day, states:

Af­ter con­firm­ing the re­sults of the fu­til­i­ty analy­sis and re­view­ing the un­blind­ed safe­ty and ef­fi­ca­cy da­ta and the re­sults of var­i­ous sen­si­tiv­i­ty and sub­group analy­ses, the com­pa­ny de­cid­ed to dis­con­tin­ue the necu­paranib pro­gram.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER